Jan 08, 2026
https://www.vcaonline.com/news/2026010901/airnexis-therapeutics-launches-with-200m-series-a-to-advance-phase-2-dual-pde3-4-inhibitor-an01-for-chronic-obstructive-pulmonary-disease-copd-/
Longitude Capital Management Co., LLC has invested $200M in AirNexus Therapeutics